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Introduction
5-year relative survival after adolescent and young adult 
(AYA) cancer is 82% in Europe.1 Survivors are at increased 
risk of developing subsequent primary neoplasms, 
estimated to be between 1·5 and 3·1 times higher than 
that expected from the general population.2,3
Previous large-scale studies of survivors of AYA cancers 
mostly concentrated on the risk of subsequent primary 
neoplasms after common cancers such as lymphomas, 
testicular cancer, and breast cancer.4–13 Only one study 
comprehensively investigated the risks of developing any 
subsequent primary neoplasm after each type of AYA 
cancer.3 The main finding from the study was that 
survivors of AYA cancer had a higher absolute risk of 
developing a subsequent primary neoplasm than did 
survivors of childhood or adult cancer. Survivors of 
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Summary
Background Few studies have investigated the risks of subsequent primary neoplasms after adolescent and young 
adult (AYA) cancer. We investigated the risks of specific subsequent primary neoplasms after each of 16 types of AYA 
cancer.
Methods The Teenage and Young Adult Cancer Survivor Study is a population-based cohort of 200 945 survivors of 
cancer diagnosed when aged 15–39 years in England and Wales from Jan 1, 1971, to Dec 31, 2006. The cohort was 
established using cancer registrations from the Office for National Statistics and the Welsh Cancer registry. Follow-up 
was from 5-year survival until the first occurrence of death, emigration, or study end date (Dec 31, 2012). In this 
analysis, we focus on the risk of specific subsequent primary neoplasms after 16 types of AYA cancer: breast; cervical; 
testicular; Hodgkin lymphoma (female); Hodgkin lymphoma (male); melanoma; CNS (intracranial); colorectal; 
non-Hodgkin lymphoma; thyroid; soft-tissue sarcoma; ovarian; bladder; other female genital; leukaemia; and head 
and neck cancer. We report absolute excess risks (AERs; per 10 000 person-years) and cumulative incidence of specific 
types of subsequent primary neoplasm after each type of AYA cancer.
Findings During the 2 631 326 person-years of follow-up (median follow-up 16·8 years, IQR 10·5–25·2), 
12 321 subsequent primary neoplasms were diagnosed in 11 565 survivors, most frequently among survivors of 
breast cancer, cervical cancer, testicular cancer, and Hodgkin lymphoma. AERs of any subsequent primary neoplasms 
were 19·5 per 10 000 person-years (95% CI 17·4–21·5) in survivors of breast cancer, 10·2 (8·0–12·4) in survivors of 
cervical cancer, 18·9 (16·6–21·1) in survivors of testicular cancer, 55·7 (50·4–61·1) in female survivors of Hodgkin 
lymphoma, and 29·9 (26·3–33·6) in male survivors of Hodgkin lymphoma. The cumulative incidence of all 
subsequent primary neoplasms 35 years after diagnosis was 11·9% (95% CI 11·3–12·6) in survivors of breast cancer, 
15·8% (14·8–16·7) in survivors of cervical cancer, 20·2% (18·9–21·5) in survivors of testicular cancer, 26·6% 
(24·7–28·6) in female survivors of Hodgkin lymphoma, and 16·5% (15·2–18·0) in male survivors of Hodgkin 
lymphoma. In patients who had survived at least 30 years from diagnosis of cervical cancer, testicular cancer, 
Hodgkin lymphoma in women, breast cancer, and Hodgkin lymphoma in men, we identified a small number of 
specific subsequent primary neoplasms that account for 82%, 61%, 58%, 45%, and 41% of the total excess number 
of neoplasms, respectively. Lung cancer accounted for a notable proportion of the excess number of neoplasms 
across all AYA groups investigated.
Interpretation Our finding that a small number of specific subsequent primary neoplasms account for a large 
percentage of the total excess number of neoplasms in long-term survivors of cervical, breast, and testicular cancer, 
and Hodgkin lymphoma provides an evidence base to inform priorities for clinical long-term follow-up. The 
prominence of lung cancer after each of these AYA cancers indicates the need for further work aimed at preventing 
and reducing the burden of this cancer in future survivors of AYA cancer.
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primary breast cancer and primary Hodgkin lymphoma 
had the highest absolute excess risk (54·4 and 48·6 per 
10 000 person-years, respectively). However, the study did 
not investigate the risks of specific subsequent primary 
neoplasms after each specific type of AYA cancer.
Evidence from previous studies of childhood cancer 
survivors suggests that the principal factors determining 
risks of subsequent primary neoplasms relate to aspects 
of treatments received for the original cancer.14–16 
Treatment of AYA cancer varies greatly by cancer type 
and therefore, in the absence of detailed treatment 
information, it is essential to stratify risks by specific 
types of AYA cancer; such risk stratification provides an 
evidence base for clinical follow-up.
The aims of this large-scale population-based study 
were to calculate risks of all and specific subsequent 
primary neoplasms after each type of AYA cancer and to 
explore variation in these risks in relation to years from 
diagnosis, age at diagnosis, decade of diagnosis, and sex.
Methods
Study design and participants
The Teenage and Young Adult Cancer Survivor Study 
(TYACSS) was established using cancer registrations 
relating to neoplasms diagnosed between Jan 1, 1971, and 
Dec 31, 2006, in individuals aged 15–39 years inclusive, 
which were obtained from the Office for National 
Statistics for English cancer registrations, and the Welsh 
Cancer Intelligence and Surveillance Unit, Public Health 
Wales, for Welsh cancer registrations. Both tumour-
related (eg, tumour site, morphology, date of diagnosis) 
and patient-related (eg, sex, date of birth, National Health 
Service [NHS] number, and unique patient identifier) 
information were obtained. The cancer registrations 
were checked for any errors, such as missing data in 
essential variables (including sex, date of birth, date of 
diagnosis, tumour site, and tumour histology) and 
incorrect chronology of events (birth, cancer, death). 
Cancer registrations were excluded if the neoplasm was 
not malignant (apart from intracranial, intraspinal, and 
bladder neoplasms where any behaviour was allowed), 
the histological type was not in the International 
Classification of Diseases for Oncology classification, the 
histological type was a non-melanoma skin cancer (these 
are underascertained by cancer registries), or if they were 
duplicate registrations. Individuals who had not survived 
5 years from their first neoplasm were excluded. We also 
excluded individuals who had a previous childhood 
cancer included in the British Childhood Cancer Survivor 
Study.17 If an individual had multiple neoplasms 
diagnosed as an AYA cancer, then the first was regarded 
as the index cancer for the cohort. The process to create 
the cohort is described in the appendix (p 2). The 
resulting cohort of 200 945 5-year survivors of AYA cancer 
was linked to the national cancer and death registers via 
NHS Digital. This enabled ascertainment of all cancers 
and deaths for patients in the TYACSS cohort up to and 
including Dec 31, 2012. Ethical approval was provided by 
the National Research Ethics Service and permission to 
process information without individual consent by the 
National Information Governance Board for Health and 
Social Care.
Research in context
Evidence before this study
The risks of subsequent primary neoplasms in survivors of 
adolescent and young adult (AYA) cancers are largely unknown. 
We searched PubMed without any language or date restrictions 
using the keywords “teenage and young adult cancer OR 
adolescent and young adult cancer” and “survivor OR 
long-term” and “second cancer OR subsequent cancer” on 
Feb 16, 2016, for articles describing subsequent primary 
neoplasms in this population. A more focused search using each 
specific AYA cancer as keywords (eg, “Hodgkin lymphoma”) in 
place of “teenage and young adult cancer OR adolescent and 
young adult cancer” was also done. Additionally, we examined 
the bibliographies of selected references. Subsequent searches 
were done on Dec 31, 2016, and July 15, 2018. Most previous 
publications included the more common AYA cancers, but were 
not restricted to AYA cancer survivors. We identified only 
one study that investigated the risk of subsequent primary 
neoplasms after the entire spectrum of AYA cancers diagnosed 
at 15–39 years of age.
Added value of this study
To our knowledge, this is the largest study to investigate the risks 
of subsequent primary neoplasm after each specific AYA cancer 
and the first to provide excess risks of specific types of subsequent 
primary neoplasm after each of 16 types of AYA cancer. Unlike 
previous studies, which focused on the multiplicative risk, 
we concentrated on the absolute excess risk—ie, the excess 
number of subsequent primary neoplasms beyond those 
expected from the general population, which is directly 
interpretable in terms of adverse health impact on survivors. 
Our study shows that the excess number of subsequent primary 
neoplasms increased with increasing years from diagnosis for all 
AYA cancers investigated in detail. Additionally, we identified a 
small number of specific subsequent primary neoplasms that 
account for a substantial proportion of the total excess number of 
neoplasms in survivors of breast cancer, cervical cancer, testicular 
cancer, and Hodgkin lymphoma.
Implications of all the available evidence
Our findings advance previous knowledge on the risks of 
subsequent neoplasms after AYA cancer and provide an 
evidence base for identifying priorities for clinical follow-up of 
survivors of AYA cancer. Because lung cancer accounted for a 
notable proportion of the excess number of neoplasms across 
all AYA groups investigated, there is need for work aimed at 
reducing this burden among future survivors.
See Online for appendix
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Procedures
Information on cancer diagnosis, sex, age at cancer 
diagnosis, decade of cancer diagnosis, and years since 
diagnosis were derived from the cancer registration 
information. Treatment information was not available 
because our sole source of data was national cancer 
registration. First primary neoplasms were grouped 
according to the internationally acknowledged classifi-
cation scheme for tumours diagnosed in adolescence 
and young adulthood.18 Carcinomas and germ cell 
tumours were further subdivided by anatomical site 
because of the implications of radiotherapy site for the 
risk of subsequent primary neoplasm (appendix pp 3–5). 
We aimed to produce risk estimates after each specific 
first primary neoplasm; therefore, survivors of cancers 
categorised as “other” cancers were not included 
(appendix pp 2, 6). We focused on the risk of specific 
subsequent primary neoplasms after 16 types of AYA 
cancer: breast; cervical; testicular; Hodgkin lymphoma 
(female); Hodgkin lymphoma (male); melanoma; CNS 
(intracranial); colorectal; non-Hodgkin lymphoma; 
thyroid; soft-tissue sarcoma; ovarian; bladder; other 
female genital; leukaemia; and head and neck cancer. 
Age at diagnosis was categorised using 5-year age bands, 
which divided the total period equally (15–39 years). 
Decade of diagnosis was divided into 1971–79, 1980–89, 
and 1990–2006, in order to broadly describe differences 
in treatment given in these periods (early chemotherapy, 
chemotherapy, and modern treatment era). Years since 
diagnosis were classified using 10-year bands following 
diagnosis.
Individual patient record linkage to national cancer 
registries enabled data to be obtained indicating when 
an individual in the cohort had a subsequent cancer 
registration. Subsequent cancer registrations were 
classified as a subsequent primary neoplasm according 
to the International Association of Cancer Registries 
(IACR) and International Agency for Research on 
Cancer (IARC) rules for determining multiple primary 
tumours using the IACR/IARC Tools software. 
To reduce the likelihood of a local spread of the original 
AYA cancer being classified as a subsequent primary 
neoplasm, potential subsequent primary neoplasms 
occurring in anatomical sites close to the first primary 
neoplasm were excluded (appendix pp 7–8). Addition-
ally, we excluded any cancer in a contralateral paired 
organ. Consequently, reported risk estimates are 
inevitably conservative.
Statistical analysis
Individuals were followed from 5-year survival until the 
first occurrence of death, emigration, or study end date 
(Dec 31, 2012). Standardised incidence ratios (SIRs) were 
calculated as observed over expected numbers of 
neoplasms. Absolute excess risks (AERs) were calculated 
as the observed minus expected number of neoplasms, 
divided by the person-years at risk and multiplied by 
10 000. The expected number of neoplasms was derived 
by multiplying the number of person-years accrued, 
stratified by sex, attained age (5-year bands), and calendar 
year (1-year bands) by the corresponding cancer rate in 
the general population of England and Wales,19 and 
summing appropriately. For AYA cancers with 200 or 
more observed subsequent primary neoplasms, SIRs are 
reported by specific type of subsequent primary neoplasm. 
We restrict attention to first primary neoplasm/
subsequent primary neoplasm combinations with at least 
100 subsequent primary neoplasms and a statistically 
significant SIR. We also identify those first primary 
neoplasm/subsequent primary neoplasm combinations 
with between 25 and 99 subsequent primary neoplasms 
and a statistically significant SIR of at least 5. We 
considered SIRs to be statistically significant at the 5% 
level (two-tailed test) if the 95% CI did not include 1. 
We considered AERs to be statistically significant at the 
5% level (two-tailed test) if the 95% CI did not include 0.
AERs were stratified by years from diagnosis, age at 
diagnosis, decade of diagnosis, and sex where there were 
at least 100 subsequent primary neoplasms. To explore 
the simultaneous effect of these explanatory factors, 
multivariable Poisson regression incorporating the 
expected number of events was used to derive relative 
excess risks (RERs).20 RERs can be interpreted as the ratio 
of AERs adjusted for other potential explanatory factors 
included within the statistical model. The key assumption 
of Poisson regression (mean=variance) was met, and 
there was no evidence of overdispersion. AERs by an 
explanatory factor are reported if both the univariable and 
multivariable tests for linear trend in the AERs were each 
significant and the difference in the AERs between the 
lowest and highest level of the risk factor was at least nine 
excess subsequent primary neoplasms. A likelihood ratio 
test was used to test for linear trend in a factor by 
comparing the log-likelihood of a model including the 
variable of interest with the log-likelihood of a model 
without the variable of interest. Resulting p values are 
presented. Two-sided p values <0·05 were considered 
statistically significant. In deciding the percentage of the 
total AER attributable to specific subsequent primary 
neoplasms in relation to years from diagnosis, we ignored 
negative values for the AER and focused only on the 
positive values. Thus, the total AER (for the purposes of 
calculating percentages) after each specific first primary 
neoplasm is the sum of the positive values for the 
contributing subsequent primary neoplasms.
Cumulative incidence was calculated treating death 
as a competing risk. Multiple subsequent primary 
neoplasms within an individual were allowed for and 
counted in all analyses involving observed and expected 
numbers of subsequent primary neoplasms. This 
approach avoided bias because the expected numbers 
(based on cancer registrations in the general population) 
count all subsequent primary neoplasms. Analyses were 
done with Stata version 14.1.
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We did sensitivity analyses in which subsequent 
leukaemia was included among survivors of AYA Hodgkin 
lymphoma, leukaemia, and non-Hodgkin lymphoma, and 
subsequent sarcoma was included among survivors of 
soft-tissue sarcoma and bone tumours.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. CJB, RCR, DLW, and MMH had access to the 
raw data. The corresponding author had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
The TYACSS cohort comprises 200 945 5-year survivors of 
cancer diagnosed when aged 15–39 years, between 
Jan 1, 1971, and Dec 31, 2006, in England and Wales. 
Cohort characteristics are shown in table 1. 3118 individuals 
with “other” cancers were excluded from the analysis 
(appendix pp 2, 6). During the 2 631 326 person-years of 
follow-up (median follow-up 16·8 years, IQR 10·5–25·2), 
12 321 subsequent primary neoplasms were diagnosed in 
11 565 (6%) of the 197 827 survivors included in the 
analysis. Subsequent primary neoplasms were most 
frequently seen in survivors of breast cancer (1877 [15%] of 
12 321 subsequent primary neoplasms), cervical cancer 
(1675 [14%]), Hodgkin lymphoma (1606 [13%]), and 
testicular cancer (1435 [12%]; table 1). Median follow-up 
was 14·3 years (IQR 9·1–22·3) in survivors of breast 
cancer, 20·2 years (12·8–27·2) in survivors of cervical 
cancer, 17·7 years (11·7–25·3) in survivors of testi-
cular cancer, 19·3 years (12·3–27·0) in female survivors of 
Hodgkin lymphoma, and 19·6 years (12·1–27·5) in male 
survivors of Hodgkin lymphoma. Investigation of all first 
primary neoplasm/subsequent primary neoplasm com-
binations with at least 100 subsequent primary neoplasms 
showed that neither age at diagnosis nor decade of 
diagnosis was systematically associated with AERs, apart 
from age at diagnosis for breast cancer after female 
Hodgkin lymphoma and decade of diagnosis for lung 
cancer after male Hodgkin lymphoma (appendix p 9). 
Consequently, in this report we consider only variation of 
AERs with years from diagnosis and sex.
Female survivors of breast cancer had an excess risk of 
developing any subsequent primary neoplasm cor-
responding to 20 excess subsequent primary neoplasms 
per 10 000 person-years (SIR 1·8, 95% CI 1·7–1·8; AER 
19·5 per 10 000 person-years, 95% CI 17·4–21·5; table 2). 
SIRs for subsequent primary cancers of ovarian, lung, 
corpus uteri, other genital, melanoma, and colorectal 
sites were statistically significantly increased (table 3). 
The total AER of developing any subsequent primary 
neoplasm increased statistically significantly with time 
from breast cancer diagnosis to an AER of 25·6 per 
10 000 person-years (95% CI 10·4–40·8) subsequent to 
30 years from diagnosis (p<0·0001; table 4). Similarly, 
the AER for developing lung cancer after breast 
cancer increased statistically significantly with years 
from diagnosis (p<0·0001; table 4). In patients who had 
survived at least 30 years, the AER for lung cancer 
(13·1 per 10 000 person-years, 95% CI 5·1–21·0) 
accounted for 45% of the total number of excess 
5-year survivors 
(n=200 945)
Subsequent 
primary neoplasms 
(n=12 321)
Sex
Male 76 666 (38%) 4282 (35%)
Female 124 279 (62%) 8039 (65%)
Age at diagnosis of AYA cancer (years)
15–19 12 248 (6%) 622 (5%)
20–24 21 258 (11%) 991 (8%)
25–29 35 894 (18%) 1768 (14%)
30–34 54 541 (27%) 3333 (27%)
35–39 77 004 (38%) 5607 (46%)
Decade of diagnosis of AYA cancer
1971–79 25 158 (13%) 4222 (34%)
1980–89 51 573 (26%) 5017 (41%)
1990–2006 124 214 (62%) 3082 (25%)
AYA cancer
Breast 36 236 (18%) 1877 (15%)
Testicular 24 309 (12%) 1435 (12%)
Cervix 23 281 (12%) 1675 (14%)
Melanoma 22 446 (11%) 981 (8%)
Hodgkin lymphoma 16 971 (8%) 1606 (13%)
Non-Hodgkin lymphoma 9467 (5%) 511 (4%)
Thyroid 7809 (4%) 473 (4%)
CNS (intracranial)* 14 616 (7%) 739 (6%)
Colorectal 5805 (3%) 537 (4%)
Soft-tissue sarcoma 6130 (3%) 400 (3%)
Ovary 4885 (2%) 349 (3%)
Leukaemia 5073 (3%) 234 (2%)
Bladder 4685 (2%) 344 (3%)
Head and neck 3961 (2%) 253 (2%)
Lung 1219 (<1%) 80 (<1%)
Female genital (other)† 2270 (1%) 269 (2%)
Spinal cord and other CNS 2602 (1%) 191 (2%)
Other digestive 1419 (<1%) 107 (<1%)
Urinary (other)‡ 1979 (1%) 139 (1%)
Bone tumour 2241 (1%) 100 (<1%)
Male genital (other)§ 423 (<1%) 21 (<1%)
Other 3118 (2%) ··¶
Time since diagnosis of AYA cancer (years)
5–9 46 679 (23%) 1863 (15%)
10–19 75 801 (38%) 4381 (36%)
20–29 50 793 (25%) 4285 (35%)
≥30 27 672 (14%) 1792 (15%)
Data are n (%). AYA=adolescent and young adult. *CNS intracranial including 
brain, meninges, and pituitary gland. †Female genital excluding cervix and ovary. 
‡Urinary excluding bladder. §Male genital excluding testis. ¶Other AYA cancers 
were not included in the analysis of subsequent primary neoplasms.
Table 1: Cohort characteristics
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neoplasms (total AER 28·9 per 10 000 person-years when 
negative AERs are excluded). The cumulative incidence 
of lung subsequent primary neoplasms at 35 years from 
diagnosis was 2·9% (95% CI 2·5–3·2), whereas an 
incidence of 2·0% was expected (figure, table 5).
Survivors of cervical cancer had an excess risk of 
developing any subsequent primary neoplasm corres-
ponding to ten excess subsequent primary neoplasms 
per 10 000 person-years (SIR 1·3, 95% CI 1·2–1·3; 
AER 10·2 per 10 000 person-years, 95% CI 8·0–12·4; 
All† Breast Cervix Testicular Hodgkin lymphoma 
(female)
Hodgkin lymphoma 
(male)
Melanoma CNS (intracranial) Colorectal Non-Hodgkin 
lymphoma
Thyroid Soft-tissue 
sarcoma
Ovary Bladder Female genital 
(other)
Leukaemia Head and neck
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
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exp
SIR 
(95% CI)
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exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
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exp
SIR 
(95% CI)
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exp
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exp
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Obs/ 
exp
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exp
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(95% CI)
Obs/ 
exp
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(95% CI)
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exp
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(95% CI)
Obs/ 
exp
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(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Breast 2260/ 
2032·1
1·1 
(1·1–1·2)
·· ·· 532/ 
684·8‡
0·8 
(0·7–0·8)‡
·· ·· 431/ 
136·3‡
3·2 
(2·9–3·5)‡
·· ·· 359/ 
313·2
1·1 
(1·0–1·3)
100/ 
145·6‡
0·7 
(0·6–0·8)‡
74/ 
79·3
0·9 
(0·7–1·2)
89/ 
70·9
1·3 
(1·0–1·5)
170/ 
130·2‡
1·3 
(1·1–1·5)‡§
88/ 
72·5
1·2 
(1·0–1·5)
101/ 
131·1‡
0·8 
(0·6–0·9)‡
29/ 
39·3
0·7 
(0·5–1·1)
80/ 
71·2
1·1 
(0·9–1·4)
50/ 
30·3
1·6 
(1·2–2·2)
44/ 
39·2
1·1 
(0·8–1·5)
Lung and 
bronchus
1740/ 
855·8
2·0 
(1·9–2·1)
357/ 
152·2‡
2·3 
(2·1–2·6)‡
335/ 
116·9‡
2·9 
(2·6–3·2)‡
171/ 
115·5‡
1·5 
(1·3–1·7)‡
101/ 
19·0‡
5·3 
(4·3–6·5)‡
198/ 
41·3‡
4·8 
(4·1–5·5)‡
82/ 
78·1
1·1 
(0·8–1·3)
34/ 
47·5
0·7 
(0·5–1·0)
48/ 
38·1
1·3 
(0·9–1·7)
83/ 
37·0
2·2 
(1·8–2·8)
34/ 
28·4
1·2 
(0·8–1·7)
32/ 
27·7
1·2 
(0·8–1·6)
54/ 
23·2
2·3 
(1·7–3·0)
73/ 
45·2
1·6 
(1·3–2·0)
29/ 
14·2
2·0 
(1·4–2·9)
14/ 
9·9
1·4 
(0·8–2·4)
41/ 
23·0
1·8 
(1·3–2·4)
Colorectal 1290/ 
801·9
1·6 
(1·5–1·7)
179/ 
150·2‡
1·2 
(1·0–1·4)‡¶
237/ 
115·1‡
2·1 
(1·8–2·3)‡
206/ 
109·2‡
1·9 
(1·6–2·2)‡
50/ 
20·2
2·5 
(1·8–3·3)
86/ 
39·2
2·2 
(1·8–2·7)
80/ 
77·5
1·0 
(0·8–1·3)
50/ 
46·8
1·1 
(0·8–1·4)
·· ·· 47/ 
35·4
1·3 
(1·0–1·8)
33/ 
28·2
1·2 
(0·8–1·6)
46/ 
26·6
1·7 
(1·3–2·3)
58/ 
23·0
2·5 
(1·9–3·3)
39/ 
39·8
1·0 
(0·7–1·3)
65/ 
13·7
4·7 
(3·6–6·0)
16/ 
10·5
1·5 
(0·9–2·5)
23/ 
21·2
1·1 
(0·7–1·6)
Other 793/ 
405·1
2·0 
(1·8–2·1)
97/ 
56·7
1·7 
(1·4–2·1)
61/ 
46·6
1·3 
(1·0–1·6)
104/ 
52·4‡
2·0 
(1·6–2·4)‡
37/ 
6·4
5·8 
(4·1–8·0)
54/ 
27·7
1·9 
(1·5–2·5)
64/ 
42·4
1·5 
(1·1–1·9)
96/ 
31·5
3·1 
(2·5–3·7)
31/ 
17·1
1·8 
(1·2–2·5)
33/ 
16·7
2·0 
(1·3–2·7)
33/ 
15·2
2·2 
(1·4–2·9)
19/ 
14·1
1·3 
(0·7–2)
19/ 
9·4
2·0 
(1·1–2·9)
26/ 
19·1
1·4 
(0·8–1·9)
15/ 
5·2
2·9 
(1·4–4·3)
15/ 
7·3
2·1 
(1·0–3·1)
28/ 
11·6
2·4 
(1·5–3·3)
Bladder 606/ 
296·6
2·0 
(1·9–2·2)
50/ 
38·6
1·3 
(1·0–1·7)
126/ 
29·6‡
4·3 
(3·5–5·1)‡
167/ 
61·3‡
2·7 
(2·3–3·2)‡
11/ 
4·9
2·2 
(1·1–4·0)
30/ 
22·0
1·4 
(0·9–1·9)
27/ 
27·8
1·0 
(0·6–1·4)
22/ 
19·2
1·1 
(0·7–1·7)
32/ 
15·5
2·1 
(1·4–2·9)
33/ 
16·5
2·0 
(1·4–2·8)
11/ 
9·4
1·2 
(0·6–2·1)
13/ 
11·2
1·2 
(0·6–2·0)
24/ 
6·0
4·0 
(2·6–6·0)
·· ·· 20/ 
3·6
5·5 
(3·4–8·5)
8/ 
4·4
1·8 
(0·8–3·6)
14/ 
10·1
1·4 
(0·8–2·3)
Prostate 545/ 
433·5
1·3 
(1·2–1·4)
·· ·· ·· ·· 185/ 
133·5‡
1·4 
(1·2–1·6)‡
·· ·· 48/ 
45·8
1·0 
(0·8–1·4)
40/ 
32·9
1·2 
(0·9–1·7)
34/ 
29·0
1·2 
(0·8–1·6)
33/ 
27·3
1·2 
(0·8–1·7)
35/ 
29·8
1·2 
(0·8–1·6)
14/ 
9·1
1·5 
(0·8–2·6)
24/ 
17·8
1·4 
(0·9–2·0)
·· ·· 62/ 
46·4
1·3 
(1·0–1·7)
·· ·· 5/ 
6·1
0·8 
(0·3–1·9)
15/ 
19·6
0·8 
(0·4–1·3)
Melanoma 500/ 
385·6
1·3 
(1·2–1·4)
100/ 
81·0‡
1·2 
(1·0–1·5)‡||
61/ 
68·3
0·9 
(0·7–1·1)
68/ 
44·4
1·5 
(1·2–1·9)
29/ 
17·1
1·7 
(1·1–2·4)
20/ 
16·8
1·2 
(0·7–1·8)
·· ·· 37/ 
26·8
1·4 
(1·0–1·9)
20/ 
13·7
1·5 
(0·9–2·3)
27/ 
17·2
1·6 
(1·0–2·3)
25/ 
17·4
1·4 
(0·9–2·1)
24/ 
13·2
1·8 
(1·2–2·7)
19/ 
13·6
1·4 
(0·8–2·2)
14/ 
13·1
1·1 
(0·6–1·8)
6/ 
6·6
0·9 
(0·3–2·0)
12/ 
7·3
1·6 
(0·8–2·9)
†† ††
Ovary 447/ 
244·6
1·8 
(1·7–2·0)
291/ 
104·9‡
2·8 
(2·5–3·1)‡
·· ·· ·· ·· 16/ 
16·4
1·0 
(0·6–1·6)
·· ·· 32/ 
37·7
0·8 
(0·6–1·2)
20/ 
17·5
1·1 
(0·7–1·8)
19/ 
10·2
1·9 
(1·1–2·9)
11/ 
8·6
1·3 
(0·6–2·3)
16/ 
15·8
1·0 
(0·6–1·6)
18/ 
9·1
2·0 
(1·2–3·1)
·· ·· †† †† ·· ·· †† †† †† ††
Oral 406/ 
215·3
1·9 
(1·7–2·1)
44/ 
28·3
1·6 
(1·1–2·1)
42/ 
23·2
1·8 
(1·3–2·4)
56/ 
40·7
1·4 
(1·0–1·8)
21/ 
4·6
4·6 
(2·8–7·0)
51/ 
14·8
3·5 
(2·6–4·5)
13/ 
20·8
0·6 
(0·3–1·1)
18/ 
13·9
1·3 
(0·8–2·0)
16/ 
8·8
1·8 
(1·0–2·9)
31/ 
11·0
2·8 
(1·9–4·0)
13/ 
7·0
1·9 
(1·0–3·2)
16/ 
7·5
2·1 
(1·2–3·5)
10/ 
4·5
2·2 
(1·1–4·1)
12/ 
10·9
1·1 
(0·6–1·9)
7/ 
2·4
2·9 
(1·2–5·9)
29/ 
3·7‡‡
7·8 
(5·2–11·1)‡‡
·· ··
Corpus uteri 404/ 
214·8
1·9 
(1·7–2·1)
204/ 
95·7‡
2·1 
(1·8–2·4)‡
·· ·· ·· ·· 21/ 
12·8
1·6 
(1·0–2·5)
·· ·· 33/ 
32·6
1·0 
(0·7–1·4)
26/ 
14·6
1·8 
(1·2–2·6)
68/ 
9·5‡‡
7·2 
(5·6–9·1)‡‡
8/ 
7·3
1·1 
(0·5–2·2)
11/ 
13·5
0·8 
(0·4–1·5)
11/ 
8·0
1·4 
(0·7–2·5)
·· ·· †† †† ·· ·· †† †† 7/ 
4·3
1·6 
(0·7–3·4)
Kidney 371/ 
175·8
2·1 
(1·9–2·3)
39/ 
27·9
1·4 
(1·0–1·9)
32/ 
22·2
1·4 
(1·0–2·0)
53/ 
30·4
1·7 
(1·3–2·3)
11/ 
4·0
2·7 
(1·4–4·9)
23/ 
11·0
2·1 
(1·3–3·1)
31/ 
17·4
1·8 
(1·2–2·5)
73/ 
11·2‡‡
6·5 
(5·1–8·2)‡‡
23/ 
7·7
3·0 
(1·9–4·5)
11/ 
8·8
1·3 
(0·6–2·2)
10/ 
6·0
1·7 
(0·8–3·0)
14/ 
6·2
2·3 
(1·2–3·8)
6/ 
4·3
1·4 
(0·5–3·0)
·· ·· †† †† 7/ 
2·8
2·5 
(1·0–5·2)
13/ 
4·9
2·6 
(1·4–4·5)
Non-Hodgkin 
lymphoma
358/ 
290·4
1·2 
(1·1–1·4)
79/ 
57·2
1·4 
(1·1–1·7)
51/ 
46·0
1·1 
(0·8–1·5)
63/ 
46·2
1·4 
(1·0–1·7)
·· ·· ·· ·· 41/ 
32·1
1·3 
(0·9–1·7)
25/ 
20·1
1·2 
(0·8–1·8)
19/ 
12·7
1·5 
(0·9–2·3)
·· ·· 13/ 
11·6
1·1 
(0·6–1·9)
13/ 
10·8
1·2 
(0·6–2·1)
8/ 
9·1
0·9 
(0·4–1·7)
11/ 
14·0
0·8 
(0·4–1·4)
6/ 
5·1
1·2 
(0·4–2·6)
·· ·· 9/ 
8·0
1·1 
(0·5–2·1)
Brain 317/ 
186·7
1·7 
(1·5–1·9)
28/ 
29·4
1·0 
(0·6–1·4)
22/ 
24·0
0·9 
(0·6–1·4)
26/ 
28·9
0·9 
(0·6–1·3)
11/ 
5·4
2·0 
(1·0–3·6)
16/ 
11·4
1·4 
(0·8–2·3)
45/ 
18·4
2·4 
(1·8–3·3)
34/ 
6·8‡‡
5·0 
(3·5–7·0)‡‡
21/ 
7·0
3·0 
(1·8–4·6)
9/ 
8·8
1·0 
(0·5–1·9)
13/ 
6·6
2·0 
(1·0–3·4)
13/ 
6·3
2·1 
(1·1–3·5)
†† †† 8/ 
8·0
1·0 
(0·4–2·0)
5/ 
2·6
1·9 
(0·6–4·5)
17/ 
3·3
5·1 
(3·0–8·2)
9/ 
4·6
2·0 
(0·9–3·7)
Oesophagus 297/ 
158·4
1·9 
(1·7–2·1)
46/ 
20·4
2·3 
(1·6–3·0)
23/ 
15·6
1·5 
(0·9–2·2)
46/ 
29·8
1·5 
(1·1–2·1)
26/ 
2·6‡‡
10·2 
(6·6–14·9)‡‡
46/ 
10·7
4·3 
(3·2–5·8)
14/ 
14·1
1·0 
(0·5–1·7)
6/ 
9·5
0·6 
(0·2–1·4)
12/ 
7·3
1·6 
(0·8–2·9)
20/ 
8·0
2·5 
(1·5–3·9)
5/ 
4·7
1·1 
(0·3–2·5)
5/ 
5·5
0·9 
(0·3–2·1)
†† †† 7/ 
9·6
0·7 
(0·3–1·5)
5/ 
1·9
2·6 
(0·9–6·1)
14/ 
2·2
6·3 
(3·4–10·6)
13/ 
4·8
2·7 
(1·5–4·7)
Pancreas 283/ 
162·8
1·7 
(1·5–2·0)
34/ 
30·3
1·1 
(0·8–1·6)
26/ 
23·0
1·1 
(0·7–1·7)
76/ 
20·9
3·6 
(2·9–4·6)
13/ 
3·8
3·4 
(1·8–5·8)
22/ 
7·5
2·9 
(1·8–4·4)
19/ 
15·1
1·3 
(0·8–2·0)
22/ 
9·0
2·4 
(1·5–3·7)
9/ 
6·9
1·3 
(0·6–2·5)
8/ 
6·8
1·2 
(0·5–2·3)
6/ 
5·5
1·1 
(0·4–2·4)
†† †† 9/ 
4·6
1·9 
(0·9–3·7)
11/ 
7·8
1·4 
(0·7–2·5)
5/ 
2·8
1·8 
(0·6–4·1)
†† †† †† ††
Other female 
genital
282/ 
219·7
1·3 
(1·1–1·4)
111/ 
82·0‡
1·4 
(1·1–1·6)‡
·· ·· ·· ·· 31/ 
19·8
1·6 
(1·1–2·2)
·· ·· 25/ 
35·9
0·7 
(0·5–1·0)
22/ 
18·1
1·2 
(0·8–1·8)
27/ 
8·1
3·3 
(2·2–4·8)
13/ 
8·4
1·5 
(0·8–2·6)
16/ 
15·5
1·0 
(0·6–1·7)
8/ 
8·6
0·9 
(0·4–1·8)
·· ·· 7/ 
4·1
1·7 
(0·7–3·5)
·· ·· 9/ 
4·2
2·1 
(1·0–4·0)
7/ 
4·4
1·6 
(0·6–3·3)
Stomach 264/ 
147·6
1·8 
(1·6–2·0)
32/ 
20·4
1·6 
(1·1–2·2)
22/ 
15·2
1·4 
(0·9–2·2)
81/ 
25·7
3·2 
(2·5–3·9)
7/ 
2·8
2·5 
(1·0–5·2)
26/ 
9·4
2·8 
(1·8–4·1)
7/ 
13·1
0·5 
(0·2–1·1)
6/ 
8·8
0·7 
(0·3–1·5)
14/ 
6·9
2·0 
(1·1–3·4)
18/ 
7·3
2·5 
(1·5–3·9)
10/ 
4·5
2·2 
(1·1–4·1)
13/ 
5·1
2·6 
(1·4–4·4)
†† †† 12/ 
9·0
1·3 
(0·7–2·3)
†† †† †† †† †† ††
Other 
digestive§§
254/ 
89·7
2·8 
(2·5–3·2)
47/ 
18·3
2·6 
(1·9–3·4)
31/ 
14·3
2·2 
(1·5–3·1)
39/ 
9·6
4·1 
(2·9–5·6)
9/ 
2·5
3·5 
(1·6–6·7)
12/ 
3·5
3·4 
(1·8–6·0)
12/ 
8·7
1·4 
(0·7–2·4)
8/ 
5·0
1·6 
(0·7–3·2)
48/ 
3·4‡‡
13·9 
(10·3–18·4)‡‡
†† †† 9/ 
3·2
2·8 
(1·3–5·3)
11/ 
2·8
4·0 
(2·0–7·1)
8/ 
2·8
2·8 
(1·2–5·6)
†† †† 6/ 
1·7
3·6 
(1·3–7·9)
†† †† †† ††
Thyroid 244/ 
90·8
2·7 
(2·4–3·0)
35/ 
20·4
1·7 
(1·2–2·4)
20/ 
17·5
1·1 
(0·7–1·8)
13/ 
5·4
2·4 
(1·3–4·1)
47/ 
5·1‡‡
9·2 
(6·7–12·2)‡‡
26/ 
2·1‡‡
12·3 
(8·0–18·0)‡‡
21/ 
11·0
1·9 
(1·2–2·9)
11/ 
6·0
1·8 
(0·9–3·3)
†† †† 12/ 
3·4
3·6 
(1·8–6·3)
·· ·· 9/ 
2·8
3·3 
(1·5–6·2)
9/ 
3·6
2·5 
(1·1–4·8)
†† †† 5/ 
1·6
3·1 
(1·0–7·2)
10/ 
1·7
6·0 
(2·9–11·0)
7/ 
1·7
4·2 
(1·7–8·7)
Leukaemia 229/ 
151·9
1·5 
(1·3–1·7)
51/ 
28·4
1·8 
(1·3–2·4)
28/ 
22·7
1·2 
(0·8–1·8)
39/ 
25·5
1·5 
(1·1–2·1)
·· ·· ·· ·· 15/ 
16·7
0·9 
(0·5–1·5)
23/ 
10·8
2·1 
(1·4–3·2)
9/ 
6·9
1·3 
(0·6–2·5)
·· ·· 10/ 
6·1
1·7 
(0·8–3·0)
9/ 
5·8
1·6 
(0·7–3·0)
10/ 
4·6
2·2 
(1·1–4·0)
11/ 
8·0
1·4 
(0·7–2·5)
†† †† ·· ·· †† ††
Other 
respiratory
217/ 
92·8
2·3 
(2·0–2·7)
30/ 
10·4
2·9 
(1·9–4·1)
18/ 
8·2
2·2 
(1·3–3·5)
31/ 
19·4
1·6 
(1·1–2·3)
20/ 
1·5
13·1 
(8·0–20·3)
42/ 
7·2‡‡
5·9 
(4·2–7·9)‡‡
12/ 
8·4
1·4 
(0·7–2·5)
12/ 
6·0
2·0 
(1·0–3·5)
8/ 
4·4
1·8 
(0·8–3·6)
12/ 
5·1
2·4 
(1·2–4·1)
9/ 
2·8
3·2 
(1·5–6·1)
†† †† †† †† 9/ 
6·0
1·5 
(0·7–2·9)
†† †† †† †† †† ††
Meninges 214/ 
70·8
3·0 
(2·6–3·5)
23/ 
16·9
1·4 
(0·9–2·0)
8/ 
13·8
0·6 
(0·3–1·1)
11/ 
4·2
2·6 
(1·3–4·7)
11/ 
3·0
3·7 
(1·8–6·5)
†† †† 9/ 
7·6
1·2 
(0·5–2·2)
60/ 
3·1‡‡
19·1 
(14·6–24·6)‡‡
†† †† 7/ 
2·4
2·9 
(1·2–6·0)
12/ 
3·0
4·0 
(2·0–6·9)
6/ 
2·0
3·0 
(1·1–6·5)
6/ 
2·7
2·2 
(0·8–4·9)
†† †† †† †† 13/ 
1·0
13·2 
(7·0–22·6)
†† ††
AYA=adolescent and young adult. Obs/exp=observed number of subsequent primary neoplasms/expected number of subsequent primary neoplasms. SIR=standardised incidence ratio. *Excludes potential 
subsequent primary neoplasms at the same anatomical site as the AYA cancer, represented by ··. †Includes all first primary neoplasms listed and other male genital and bone tumours. ‡At least 100 observed events 
and significant SIR. §Breast subsequent primary neoplasms after thyroid cancer occurred only in females; expected breast cancers in males was zero. ¶Confidence interval to three decimal places was 1·023–1·380. 
||Confidence interval to three decimal places was 1·004–1·501. ††Results not reliable because of small number of subsequent primary neoplasms (<5 observed subsequent primary neoplasms). ‡‡Between 25 and 
99 observed events, SIR at least 5. §§Consists of 80 small intestine, 62 gallbladder, 77 retroperitoneum and peritoneum, and 31 other or unspecified.
Table 3: Risk of specific subsequent primary neoplasms (row headings) after specific AYA cancers* (column headings) with at least 200 subsequent primary neoplasms observed in total
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table 2). SIRs for subsequent primary neoplasms of 
bladder, lung, and colorectal sites were statistically 
significantly increased. We noted a statistically significant 
reduction in the SIR related to breast cancer (SIR 0·8, 
95% CI 0·7–0·8; table 3). The total AER of developing 
any subsequent primary neoplasm increased with time 
from cervical cancer diagnosis to an AER of 32·3 per 
10 000 person-years (95% CI 15·4–49·1) subsequent to 
30 years from diagnosis (p<0·0001), as did the AER for 
developing lung, colorectal, and bladder cancer (each 
All† Breast Cervix Testicular Hodgkin lymphoma 
(female)
Hodgkin lymphoma 
(male)
Melanoma CNS (intracranial) Colorectal Non-Hodgkin 
lymphoma
Thyroid Soft-tissue 
sarcoma
Ovary Bladder Female genital 
(other)
Leukaemia Head and neck
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Obs/ 
exp
SIR 
(95% CI)
Breast 2260/ 
2032·1
1·1 
(1·1–1·2)
·· ·· 532/ 
684·8‡
0·8 
(0·7–0·8)‡
·· ·· 431/ 
136·3‡
3·2 
(2·9–3·5)‡
·· ·· 359/ 
313·2
1·1 
(1·0–1·3)
100/ 
145·6‡
0·7 
(0·6–0·8)‡
74/ 
79·3
0·9 
(0·7–1·2)
89/ 
70·9
1·3 
(1·0–1·5)
170/ 
130·2‡
1·3 
(1·1–1·5)‡§
88/ 
72·5
1·2 
(1·0–1·5)
101/ 
131·1‡
0·8 
(0·6–0·9)‡
29/ 
39·3
0·7 
(0·5–1·1)
80/ 
71·2
1·1 
(0·9–1·4)
50/ 
30·3
1·6 
(1·2–2·2)
44/ 
39·2
1·1 
(0·8–1·5)
Lung and 
bronchus
1740/ 
855·8
2·0 
(1·9–2·1)
357/ 
152·2‡
2·3 
(2·1–2·6)‡
335/ 
116·9‡
2·9 
(2·6–3·2)‡
171/ 
115·5‡
1·5 
(1·3–1·7)‡
101/ 
19·0‡
5·3 
(4·3–6·5)‡
198/ 
41·3‡
4·8 
(4·1–5·5)‡
82/ 
78·1
1·1 
(0·8–1·3)
34/ 
47·5
0·7 
(0·5–1·0)
48/ 
38·1
1·3 
(0·9–1·7)
83/ 
37·0
2·2 
(1·8–2·8)
34/ 
28·4
1·2 
(0·8–1·7)
32/ 
27·7
1·2 
(0·8–1·6)
54/ 
23·2
2·3 
(1·7–3·0)
73/ 
45·2
1·6 
(1·3–2·0)
29/ 
14·2
2·0 
(1·4–2·9)
14/ 
9·9
1·4 
(0·8–2·4)
41/ 
23·0
1·8 
(1·3–2·4)
Colorectal 1290/ 
801·9
1·6 
(1·5–1·7)
179/ 
150·2‡
1·2 
(1·0–1·4)‡¶
237/ 
115·1‡
2·1 
(1·8–2·3)‡
206/ 
109·2‡
1·9 
(1·6–2·2)‡
50/ 
20·2
2·5 
(1·8–3·3)
86/ 
39·2
2·2 
(1·8–2·7)
80/ 
77·5
1·0 
(0·8–1·3)
50/ 
46·8
1·1 
(0·8–1·4)
·· ·· 47/ 
35·4
1·3 
(1·0–1·8)
33/ 
28·2
1·2 
(0·8–1·6)
46/ 
26·6
1·7 
(1·3–2·3)
58/ 
23·0
2·5 
(1·9–3·3)
39/ 
39·8
1·0 
(0·7–1·3)
65/ 
13·7
4·7 
(3·6–6·0)
16/ 
10·5
1·5 
(0·9–2·5)
23/ 
21·2
1·1 
(0·7–1·6)
Other 793/ 
405·1
2·0 
(1·8–2·1)
97/ 
56·7
1·7 
(1·4–2·1)
61/ 
46·6
1·3 
(1·0–1·6)
104/ 
52·4‡
2·0 
(1·6–2·4)‡
37/ 
6·4
5·8 
(4·1–8·0)
54/ 
27·7
1·9 
(1·5–2·5)
64/ 
42·4
1·5 
(1·1–1·9)
96/ 
31·5
3·1 
(2·5–3·7)
31/ 
17·1
1·8 
(1·2–2·5)
33/ 
16·7
2·0 
(1·3–2·7)
33/ 
15·2
2·2 
(1·4–2·9)
19/ 
14·1
1·3 
(0·7–2)
19/ 
9·4
2·0 
(1·1–2·9)
26/ 
19·1
1·4 
(0·8–1·9)
15/ 
5·2
2·9 
(1·4–4·3)
15/ 
7·3
2·1 
(1·0–3·1)
28/ 
11·6
2·4 
(1·5–3·3)
Bladder 606/ 
296·6
2·0 
(1·9–2·2)
50/ 
38·6
1·3 
(1·0–1·7)
126/ 
29·6‡
4·3 
(3·5–5·1)‡
167/ 
61·3‡
2·7 
(2·3–3·2)‡
11/ 
4·9
2·2 
(1·1–4·0)
30/ 
22·0
1·4 
(0·9–1·9)
27/ 
27·8
1·0 
(0·6–1·4)
22/ 
19·2
1·1 
(0·7–1·7)
32/ 
15·5
2·1 
(1·4–2·9)
33/ 
16·5
2·0 
(1·4–2·8)
11/ 
9·4
1·2 
(0·6–2·1)
13/ 
11·2
1·2 
(0·6–2·0)
24/ 
6·0
4·0 
(2·6–6·0)
·· ·· 20/ 
3·6
5·5 
(3·4–8·5)
8/ 
4·4
1·8 
(0·8–3·6)
14/ 
10·1
1·4 
(0·8–2·3)
Prostate 545/ 
433·5
1·3 
(1·2–1·4)
·· ·· ·· ·· 185/ 
133·5‡
1·4 
(1·2–1·6)‡
·· ·· 48/ 
45·8
1·0 
(0·8–1·4)
40/ 
32·9
1·2 
(0·9–1·7)
34/ 
29·0
1·2 
(0·8–1·6)
33/ 
27·3
1·2 
(0·8–1·7)
35/ 
29·8
1·2 
(0·8–1·6)
14/ 
9·1
1·5 
(0·8–2·6)
24/ 
17·8
1·4 
(0·9–2·0)
·· ·· 62/ 
46·4
1·3 
(1·0–1·7)
·· ·· 5/ 
6·1
0·8 
(0·3–1·9)
15/ 
19·6
0·8 
(0·4–1·3)
Melanoma 500/ 
385·6
1·3 
(1·2–1·4)
100/ 
81·0‡
1·2 
(1·0–1·5)‡||
61/ 
68·3
0·9 
(0·7–1·1)
68/ 
44·4
1·5 
(1·2–1·9)
29/ 
17·1
1·7 
(1·1–2·4)
20/ 
16·8
1·2 
(0·7–1·8)
·· ·· 37/ 
26·8
1·4 
(1·0–1·9)
20/ 
13·7
1·5 
(0·9–2·3)
27/ 
17·2
1·6 
(1·0–2·3)
25/ 
17·4
1·4 
(0·9–2·1)
24/ 
13·2
1·8 
(1·2–2·7)
19/ 
13·6
1·4 
(0·8–2·2)
14/ 
13·1
1·1 
(0·6–1·8)
6/ 
6·6
0·9 
(0·3–2·0)
12/ 
7·3
1·6 
(0·8–2·9)
†† ††
Ovary 447/ 
244·6
1·8 
(1·7–2·0)
291/ 
104·9‡
2·8 
(2·5–3·1)‡
·· ·· ·· ·· 16/ 
16·4
1·0 
(0·6–1·6)
·· ·· 32/ 
37·7
0·8 
(0·6–1·2)
20/ 
17·5
1·1 
(0·7–1·8)
19/ 
10·2
1·9 
(1·1–2·9)
11/ 
8·6
1·3 
(0·6–2·3)
16/ 
15·8
1·0 
(0·6–1·6)
18/ 
9·1
2·0 
(1·2–3·1)
·· ·· †† †† ·· ·· †† †† †† ††
Oral 406/ 
215·3
1·9 
(1·7–2·1)
44/ 
28·3
1·6 
(1·1–2·1)
42/ 
23·2
1·8 
(1·3–2·4)
56/ 
40·7
1·4 
(1·0–1·8)
21/ 
4·6
4·6 
(2·8–7·0)
51/ 
14·8
3·5 
(2·6–4·5)
13/ 
20·8
0·6 
(0·3–1·1)
18/ 
13·9
1·3 
(0·8–2·0)
16/ 
8·8
1·8 
(1·0–2·9)
31/ 
11·0
2·8 
(1·9–4·0)
13/ 
7·0
1·9 
(1·0–3·2)
16/ 
7·5
2·1 
(1·2–3·5)
10/ 
4·5
2·2 
(1·1–4·1)
12/ 
10·9
1·1 
(0·6–1·9)
7/ 
2·4
2·9 
(1·2–5·9)
29/ 
3·7‡‡
7·8 
(5·2–11·1)‡‡
·· ··
Corpus uteri 404/ 
214·8
1·9 
(1·7–2·1)
204/ 
95·7‡
2·1 
(1·8–2·4)‡
·· ·· ·· ·· 21/ 
12·8
1·6 
(1·0–2·5)
·· ·· 33/ 
32·6
1·0 
(0·7–1·4)
26/ 
14·6
1·8 
(1·2–2·6)
68/ 
9·5‡‡
7·2 
(5·6–9·1)‡‡
8/ 
7·3
1·1 
(0·5–2·2)
11/ 
13·5
0·8 
(0·4–1·5)
11/ 
8·0
1·4 
(0·7–2·5)
·· ·· †† †† ·· ·· †† †† 7/ 
4·3
1·6 
(0·7–3·4)
Kidney 371/ 
175·8
2·1 
(1·9–2·3)
39/ 
27·9
1·4 
(1·0–1·9)
32/ 
22·2
1·4 
(1·0–2·0)
53/ 
30·4
1·7 
(1·3–2·3)
11/ 
4·0
2·7 
(1·4–4·9)
23/ 
11·0
2·1 
(1·3–3·1)
31/ 
17·4
1·8 
(1·2–2·5)
73/ 
11·2‡‡
6·5 
(5·1–8·2)‡‡
23/ 
7·7
3·0 
(1·9–4·5)
11/ 
8·8
1·3 
(0·6–2·2)
10/ 
6·0
1·7 
(0·8–3·0)
14/ 
6·2
2·3 
(1·2–3·8)
6/ 
4·3
1·4 
(0·5–3·0)
·· ·· †† †† 7/ 
2·8
2·5 
(1·0–5·2)
13/ 
4·9
2·6 
(1·4–4·5)
Non-Hodgkin 
lymphoma
358/ 
290·4
1·2 
(1·1–1·4)
79/ 
57·2
1·4 
(1·1–1·7)
51/ 
46·0
1·1 
(0·8–1·5)
63/ 
46·2
1·4 
(1·0–1·7)
·· ·· ·· ·· 41/ 
32·1
1·3 
(0·9–1·7)
25/ 
20·1
1·2 
(0·8–1·8)
19/ 
12·7
1·5 
(0·9–2·3)
·· ·· 13/ 
11·6
1·1 
(0·6–1·9)
13/ 
10·8
1·2 
(0·6–2·1)
8/ 
9·1
0·9 
(0·4–1·7)
11/ 
14·0
0·8 
(0·4–1·4)
6/ 
5·1
1·2 
(0·4–2·6)
·· ·· 9/ 
8·0
1·1 
(0·5–2·1)
Brain 317/ 
186·7
1·7 
(1·5–1·9)
28/ 
29·4
1·0 
(0·6–1·4)
22/ 
24·0
0·9 
(0·6–1·4)
26/ 
28·9
0·9 
(0·6–1·3)
11/ 
5·4
2·0 
(1·0–3·6)
16/ 
11·4
1·4 
(0·8–2·3)
45/ 
18·4
2·4 
(1·8–3·3)
34/ 
6·8‡‡
5·0 
(3·5–7·0)‡‡
21/ 
7·0
3·0 
(1·8–4·6)
9/ 
8·8
1·0 
(0·5–1·9)
13/ 
6·6
2·0 
(1·0–3·4)
13/ 
6·3
2·1 
(1·1–3·5)
†† †† 8/ 
8·0
1·0 
(0·4–2·0)
5/ 
2·6
1·9 
(0·6–4·5)
17/ 
3·3
5·1 
(3·0–8·2)
9/ 
4·6
2·0 
(0·9–3·7)
Oesophagus 297/ 
158·4
1·9 
(1·7–2·1)
46/ 
20·4
2·3 
(1·6–3·0)
23/ 
15·6
1·5 
(0·9–2·2)
46/ 
29·8
1·5 
(1·1–2·1)
26/ 
2·6‡‡
10·2 
(6·6–14·9)‡‡
46/ 
10·7
4·3 
(3·2–5·8)
14/ 
14·1
1·0 
(0·5–1·7)
6/ 
9·5
0·6 
(0·2–1·4)
12/ 
7·3
1·6 
(0·8–2·9)
20/ 
8·0
2·5 
(1·5–3·9)
5/ 
4·7
1·1 
(0·3–2·5)
5/ 
5·5
0·9 
(0·3–2·1)
†† †† 7/ 
9·6
0·7 
(0·3–1·5)
5/ 
1·9
2·6 
(0·9–6·1)
14/ 
2·2
6·3 
(3·4–10·6)
13/ 
4·8
2·7 
(1·5–4·7)
Pancreas 283/ 
162·8
1·7 
(1·5–2·0)
34/ 
30·3
1·1 
(0·8–1·6)
26/ 
23·0
1·1 
(0·7–1·7)
76/ 
20·9
3·6 
(2·9–4·6)
13/ 
3·8
3·4 
(1·8–5·8)
22/ 
7·5
2·9 
(1·8–4·4)
19/ 
15·1
1·3 
(0·8–2·0)
22/ 
9·0
2·4 
(1·5–3·7)
9/ 
6·9
1·3 
(0·6–2·5)
8/ 
6·8
1·2 
(0·5–2·3)
6/ 
5·5
1·1 
(0·4–2·4)
†† †† 9/ 
4·6
1·9 
(0·9–3·7)
11/ 
7·8
1·4 
(0·7–2·5)
5/ 
2·8
1·8 
(0·6–4·1)
†† †† †† ††
Other female 
genital
282/ 
219·7
1·3 
(1·1–1·4)
111/ 
82·0‡
1·4 
(1·1–1·6)‡
·· ·· ·· ·· 31/ 
19·8
1·6 
(1·1–2·2)
·· ·· 25/ 
35·9
0·7 
(0·5–1·0)
22/ 
18·1
1·2 
(0·8–1·8)
27/ 
8·1
3·3 
(2·2–4·8)
13/ 
8·4
1·5 
(0·8–2·6)
16/ 
15·5
1·0 
(0·6–1·7)
8/ 
8·6
0·9 
(0·4–1·8)
·· ·· 7/ 
4·1
1·7 
(0·7–3·5)
·· ·· 9/ 
4·2
2·1 
(1·0–4·0)
7/ 
4·4
1·6 
(0·6–3·3)
Stomach 264/ 
147·6
1·8 
(1·6–2·0)
32/ 
20·4
1·6 
(1·1–2·2)
22/ 
15·2
1·4 
(0·9–2·2)
81/ 
25·7
3·2 
(2·5–3·9)
7/ 
2·8
2·5 
(1·0–5·2)
26/ 
9·4
2·8 
(1·8–4·1)
7/ 
13·1
0·5 
(0·2–1·1)
6/ 
8·8
0·7 
(0·3–1·5)
14/ 
6·9
2·0 
(1·1–3·4)
18/ 
7·3
2·5 
(1·5–3·9)
10/ 
4·5
2·2 
(1·1–4·1)
13/ 
5·1
2·6 
(1·4–4·4)
†† †† 12/ 
9·0
1·3 
(0·7–2·3)
†† †† †† †† †† ††
Other 
digestive§§
254/ 
89·7
2·8 
(2·5–3·2)
47/ 
18·3
2·6 
(1·9–3·4)
31/ 
14·3
2·2 
(1·5–3·1)
39/ 
9·6
4·1 
(2·9–5·6)
9/ 
2·5
3·5 
(1·6–6·7)
12/ 
3·5
3·4 
(1·8–6·0)
12/ 
8·7
1·4 
(0·7–2·4)
8/ 
5·0
1·6 
(0·7–3·2)
48/ 
3·4‡‡
13·9 
(10·3–18·4)‡‡
†† †† 9/ 
3·2
2·8 
(1·3–5·3)
11/ 
2·8
4·0 
(2·0–7·1)
8/ 
2·8
2·8 
(1·2–5·6)
†† †† 6/ 
1·7
3·6 
(1·3–7·9)
†† †† †† ††
Thyroid 244/ 
90·8
2·7 
(2·4–3·0)
35/ 
20·4
1·7 
(1·2–2·4)
20/ 
17·5
1·1 
(0·7–1·8)
13/ 
5·4
2·4 
(1·3–4·1)
47/ 
5·1‡‡
9·2 
(6·7–12·2)‡‡
26/ 
2·1‡‡
12·3 
(8·0–18·0)‡‡
21/ 
11·0
1·9 
(1·2–2·9)
11/ 
6·0
1·8 
(0·9–3·3)
†† †† 12/ 
3·4
3·6 
(1·8–6·3)
·· ·· 9/ 
2·8
3·3 
(1·5–6·2)
9/ 
3·6
2·5 
(1·1–4·8)
†† †† 5/ 
1·6
3·1 
(1·0–7·2)
10/ 
1·7
6·0 
(2·9–11·0)
7/ 
1·7
4·2 
(1·7–8·7)
Leukaemia 229/ 
151·9
1·5 
(1·3–1·7)
51/ 
28·4
1·8 
(1·3–2·4)
28/ 
22·7
1·2 
(0·8–1·8)
39/ 
25·5
1·5 
(1·1–2·1)
·· ·· ·· ·· 15/ 
16·7
0·9 
(0·5–1·5)
23/ 
10·8
2·1 
(1·4–3·2)
9/ 
6·9
1·3 
(0·6–2·5)
·· ·· 10/ 
6·1
1·7 
(0·8–3·0)
9/ 
5·8
1·6 
(0·7–3·0)
10/ 
4·6
2·2 
(1·1–4·0)
11/ 
8·0
1·4 
(0·7–2·5)
†† †† ·· ·· †† ††
Other 
respiratory
217/ 
92·8
2·3 
(2·0–2·7)
30/ 
10·4
2·9 
(1·9–4·1)
18/ 
8·2
2·2 
(1·3–3·5)
31/ 
19·4
1·6 
(1·1–2·3)
20/ 
1·5
13·1 
(8·0–20·3)
42/ 
7·2‡‡
5·9 
(4·2–7·9)‡‡
12/ 
8·4
1·4 
(0·7–2·5)
12/ 
6·0
2·0 
(1·0–3·5)
8/ 
4·4
1·8 
(0·8–3·6)
12/ 
5·1
2·4 
(1·2–4·1)
9/ 
2·8
3·2 
(1·5–6·1)
†† †† †† †† 9/ 
6·0
1·5 
(0·7–2·9)
†† †† †† †† †† ††
Meninges 214/ 
70·8
3·0 
(2·6–3·5)
23/ 
16·9
1·4 
(0·9–2·0)
8/ 
13·8
0·6 
(0·3–1·1)
11/ 
4·2
2·6 
(1·3–4·7)
11/ 
3·0
3·7 
(1·8–6·5)
†† †† 9/ 
7·6
1·2 
(0·5–2·2)
60/ 
3·1‡‡
19·1 
(14·6–24·6)‡‡
†† †† 7/ 
2·4
2·9 
(1·2–6·0)
12/ 
3·0
4·0 
(2·0–6·9)
6/ 
2·0
3·0 
(1·1–6·5)
6/ 
2·7
2·2 
(0·8–4·9)
†† †† †† †† 13/ 
1·0
13·2 
(7·0–22·6)
†† ††
AYA=adolescent and young adult. Obs/exp=observed number of subsequent primary neoplasms/expected number of subsequent primary neoplasms. SIR=standardised incidence ratio. *Excludes potential 
subsequent primary neoplasms at the same anatomical site as the AYA cancer, represented by ··. †Includes all first primary neoplasms listed and other male genital and bone tumours. ‡At least 100 observed events 
and significant SIR. §Breast subsequent primary neoplasms after thyroid cancer occurred only in females; expected breast cancers in males was zero. ¶Confidence interval to three decimal places was 1·023–1·380. 
||Confidence interval to three decimal places was 1·004–1·501. ††Results not reliable because of small number of subsequent primary neoplasms (<5 observed subsequent primary neoplasms). ‡‡Between 25 and 
99 observed events, SIR at least 5. §§Consists of 80 small intestine, 62 gallbladder, 77 retroperitoneum and peritoneum, and 31 other or unspecified.
Table 3: Risk of specific subsequent primary neoplasms (row headings) after specific AYA cancers* (column headings) with at least 200 subsequent primary neoplasms observed in total
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p<0·0001; table 4). In patients who had survived at least 
30 years, the AERs for lung cancer (17·2 per 
10 000 person-years, 95% CI 8·8–25·6), colorectal cancer 
(10·7, 3·5–17·9), and bladder cancer (10·1, 4·5–15·7) 
accounted for 37%, 23%, and 22% of the total number of 
excess neoplasms, respectively (total AER 46·5 per 
10 000 person-years when negative AERs are excluded). 
The cumulative incidences of subsequent lung, 
colorectal, and bladder neoplasms at 35 years from 
diagnosis were 3·6% (95% CI 3·2–4·2), 2·6% (2·2–3·0), 
and 1·3% (1·0–1·6), whereas incidences of 1·6%, 1·4%, 
and 0·4% were expected, respectively (figure, table 5).
Survivors of testicular cancer had an excess risk of 
developing any subsequent primary neoplasm cor-
responding to 19 excess subsequent primary neoplasms 
per 10 000 person-years (SIR 1·8, 95% CI 1·7–1·9; 
AER 18·9 per 10 000 person-years, 95% CI 16·6–21·1; 
table 2). SIRs for subsequent primary neoplasms of 
bladder, colorectal, lung, and prostate sites were 
statistically significantly increased (table 3). The total AER 
of developing any subsequent primary neoplasm 
increased with time from testicular cancer diagnosis to an 
AER of 127·0 per 10 000 person-years (95% CI 
100·0–154·0) subsequent to 30 years from diagnosis 
(p<0·0001), as did the AER for developing bladder, 
colorectal, lung, and prostate cancer (each p<0·0001; 
table 4). In patients who had survived at least 30 years, the 
AERs for prostate cancer (25·3 per 10 000 person-years, 
95% CI 12·1–38·6), bladder cancer (22·8, 13·0–32·7), 
colorectal cancer (19·6, 9·2–29·9), and lung cancer 
(9·5, 0·1–18·8) accounted for 20%, 18%, 15%, and 8% of 
the total number of excess neoplasms, respectively. 
The cumulative incidences of subsequent primary 
neoplasms at 35 years from diagnosis were 3·7% (95% CI 
3·1–4·4) for prostate, 2·9% (95% CI 2·4–3·6) for bladder, 
3·0% (2·5–3·6) for colorectal, and 2·7% (2·2–3·2) for 
lung, whereas incidences of 2·9%, 1·1%, 1·8%, and 2·0% 
were expected, respectively (figure, table 5).
Female survivors of Hodgkin lymphoma had an excess 
risk of developing any subsequent primary neoplasm 
corresponding to 56 excess subsequent primary neo-
plasms per 10 000 person-years (SIR 3·1, 95% CI 2·9–3·3; 
AER 55·7 per 10 000 person-years, 95% CI 50·4–61·1; 
table 2). SIRs for subsequent primary cancers of breast 
and lung sites were statistically significantly increased 
(table 3). The total AER of developing any subsequent 
primary neoplasm increased with time from Hodgkin 
lymphoma diagnosis to an AER of 168·6 per 
10 000 person-years (95% CI 129·5–207·8) subsequent to 
30 years from diagnosis (p<0·0001), as did the AER for 
developing breast and lung cancer (each p<0·0001; 
table 4). In patients who had survived at least 30 years, the 
AERs for breast cancer (71·8 per 10 000 person-years, 
95% CI 46·4–97·2) and lung cancer (26·0, 11·2–40·8) 
accounted for 43% and 15% of the total number of excess 
neoplasms, respectively. The cumulative incidences of 
breast and lung neoplasms at 35 years from diagnosis 
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were 14·4% (95% CI 12·9–15·9) and 3·8% (3·0–4·8), 
whereas incidences of 4·9% and 0·9% were expected, 
respectively (figure, table 5).
Male survivors of Hodgkin lymphoma had an excess 
risk of developing any subsequent primary neoplasm 
corresponding to 30 excess subsequent primary neo-
plasms per 10 000 person-years (SIR 2·6, 95% CI 
2·4–2·8; AER 29·9 per 10 000 person-years, 95% CI 
26·3–33·6; table 2). The SIR for a subsequent primary 
lung cancer was statistically significantly increased 
(table 3). The total AER of developing any subsequent 
primary neoplasm increased with time from Hodgkin 
lymphoma diagnosis to an AER of 121·9 per 
10 000 person-years (95% CI 91·3–152·4) subsequent to 
30 years from diagnosis (p<0·0001), as did the AER for 
developing lung cancer (p<0·0001; table 4). In patients 
who had survived at least 30 years, the AER for lung 
cancer (50·2 per 10 000 person-years, 95% CI 33·0–67·3) 
accounted for 41% of the total number of excess 
neoplasms. The cumulative incidence of lung neo-
plasms in male survivors of Hodgkin lymphoma was 
5·1% (95% CI 4·3–6·0) at 35 years from diagnosis, 
whereas an incidence of 1·4% was expected (figure, 
table 5).
Female survivors of thyroid cancer had an excess risk of 
developing any subsequent primary neoplasm corres-
ponding to 13 excess subsequent primary neoplasms 
per 10 000 person-years (SIR 1·4, 95% CI 1·2–1·5; 
AER 13·1 per 10 000 person-years, 95% CI 8·4–17·8; 
table 2). The SIR for a subsequent primary breast cancer 
was statistically significantly increased (table 3). The total 
AER of developing any subsequent primary neoplasm 
increased with time from thyroid cancer diagnosis to an 
AER of 21·9 per 10 000 person-years (95% CI –10·9 to 54·7) 
subsequent to 30 years from diagnosis, (p=0·03; table 4). 
The cumulative incidence of all subsequent primary neo-
plasms in female survivors of thyroid cancer was 18·2% 
(95% CI 16·1–20·5) at 35 years from diagnosis (table 5), 
whereas an incidence of 13·6% was expected. The 
cumulative incidence of breast cancer was 8·2% (6·7–9·8) 
at 35 years from diagnosis, whereas an incidence of 6·0% 
was expected (figure; table 5).
Survivors of ovarian cancer had an excess risk 
of developing any subsequent primary neoplasm 
Figure: Observed (solid) and expected (dashed) cumulative incidence of specific subsequent primary neoplasms in survivors of adolescent and young adult cancer
*Cumulative incidence exceeds scale; please refer to table 5 for cumulative incidence up to 35 years from diagnosis.
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corresponding to 12 excess subsequent primary 
neoplasms per 10 000 person-years (SIR 1·4, 95% CI 
1·2–1·5; AER 12·3 per 10 000 person-years, 95% CI 
7·5–17·1; table 2). A statistically significant reduction 
was found in the SIR for the development of a 
subsequent primary breast cancer (0·8, 95% CI 0·6–0·9; 
table 3). The cumulative incidence of all subsequent 
primary neoplasms was 13·9% (95% CI 12·2–15·7) at 
35 years from diagnosis (table 2), whereas an incidence 
of 12·3% was expected.
Both male and female survivors of CNS tumours had 
an excess risk of developing any subsequent primary 
10 years 15 years 20 years 25 years 30 years 35 years
First primary neoplasm: female breast
Total subsequent primary 
neoplasms*
1·1% (1·0–1·2) 2·5% (2·3–2·7) 4·2% (4·0–4·5) 6·4% (6·1–6·8) 9·3% (8·8–9·8) 11·9% (11·3–12·6)
Corpus uteri 0·1% (0·1–0·2) 0·3% (0·3–0·4) 0·6% (0·5–0·7) 0·9% (0·7–1·0) 1·0% (0·9–1·2) 1·1% (1·0–1·3)
Ovary 0·2% (0·2–0·3) 0·5% (0·4–0·6) 0·8% (0·7–0·9) 1·1% (1·0–1·3) 1·4% (1·2–1·6) 1·7% (1·5–2·0)
Other female genital 0·1% (0·0–0·1) 0·2% (0·2–0·3) 0·4% (0·3–0·4) 0·6% (0·5–0·7) 1·0% (0·8–1·2) 1·5% (1·2–1·7)
Colorectal 0·1% (0·1–0·2) 0·2% (0·2–0·3) 0·3% (0·3–0·4) 0·4% (0·3–0·5) 0·5% (0·4–0·6) 0·5% (0·4–0·7)
Lung 0·1% (0·1–0·1) 0·3% (0·2–0·3) 0·7% (0·6–0·8) 1·2% (1·0–1·4) 2·2% (1·9–2·4) 2·9% (2·5–3·2)
Melanoma 0·1% (0·1–0·1) 0·2% (0·2–0·3) 0·3% (0·2–0·4) 0·4% (0·3–0·4) 0·5% (0·4–0·6) 0·5% (0·4–0·7)
Other 0·4% (0·3–0·4) 0·8% (0·7–0·9) 1·4% (1·2–1·5) 2·2% (2·0–2·4) 3·3% (3·0–3·6) 4·4% (4·0–4·8)
First primary neoplasm: cervix
Total subsequent primary 
neoplasms†
1·1% (1·0–1·2) 2·7% (2·5–2·9) 4·8% (4·5–5·1) 7·8% (7·4–8·3) 11·5% (10·9–12·1) 15·8% (14·8–16·7)
Breast 0·4% (0·3–0·5) 1·1% (1·0–1·3) 1·9% (1·7–2·1) 2·9% (2·6–3·1) 3·7% (3·3–4·0) 4·6% (4·2–5·1)
Bladder 0·0% (0·0–0·1) 0·1% (0·1–0·2) 0·3% (0·2–0·4) 0·6% (0·4–0·7) 0·9% (0·7–1·1) 1·3% (1·0–1·6)
Colorectal 0·1% (0·1–0·2) 0·2% (0·2–0·3) 0·5% (0·4–0·7) 1·1% (0·9–1·3) 1·8% (1·5–2·1) 2·6% (2·2–3·0)
Lung 0·2% (0·1–0·3) 0·5% (0·4–0·6) 0·8% (0·7–1·0) 1·4% (1·2–1·6) 2·5% (2·2–2·9) 3·6% (3·2–4·2)
Other 0·3% (0·3–0·4) 0·7% (0·6–0·9) 1·3% (1·1–1·5) 2·1% (1·8–2·3) 3·1% (2·8–3·5) 4·5% (4·0–5·1)
First primary neoplasm: testicular
Total subsequent primary 
neoplasms‡
0·6% (0·5–0·7) 1·5% (1·3–1·6) 3·2% (2·9–3·4) 6·5% (6·0–6·9) 12·2% (11·5–13·0) 20·2% (18·9–21·5)
Prostate 0·0% (0·0–0·0) 0·0% (0·0–0·1) 0·2% (0·1–0·3) 0·6% (0·4–0·8) 1·6% (1·3–1·9) 3·7% (3·1–4·4)
Bladder 0·0% (0·0–0·1) 0·1% (0·1–0·2) 0·3% (0·2–0·4) 0·8% (0·6–1·0) 1·6% (1·3–1·9) 2·9% (2·4–3·6)
Colorectal 0·1% (0·0–0·1) 0·2% (0·1–0·3) 0·4% (0·3–0·5) 0·9% (0·7–1·1) 2·0% (1·7–2·3) 3·0% (2·5–3·6)
Lung 0·0% (0·0–0·1) 0·1% (0·1–0·2) 0·3% (0·2–0·4) 0·8% (0·7–1·0) 1·6% (1·3–2·0) 2·7% (2·2–3·2)
Other 0·4% (0·3–0·5) 1·0% (0·9–1·2) 2·0% (1·8–2·3) 3·6% (3·2–3·9) 6·1% (5·6–6·7) 9·3% (8·4–10·2)
First primary neoplasm: female Hodgkin lymphoma
Total subsequent primary 
neoplasms§
0·9% (0·7–1·2) 3·2% (2·8–3·7) 7·2% (6·5–8·0) 13·0% (11·9–14·0) 20·2% (18·8–21·7) 26·6% (24·7–28·6)
Breast 0·3% (0·2–0·4) 1·3% (1·1–1·6) 3·8% (3·3–4·4) 6·7% (5·9–7·5) 10·8% (9·7–11·9) 14·4% (12·9–15·9)
Lung 0·1% (0·0–0·2) 0·3% (0·2–0·5) 0·6% (0·4–0·9) 1·5% (1·2–2·0) 2·5% (1·9–3·1) 3·8% (3·0–4·8)
Other 0·5% (0·4–0·7) 1·6% (1·3–1·9) 2·9% (2·5–3·4) 5·1% (4·5–5·8) 8·3% (7·3–9·3) 11·3% (10·0–12·7)
First primary neoplasm: male Hodgkin lymphoma
Total subsequent primary 
neoplasms¶
0·6% (0·4–0·7) 1·6% (1·3–1·9) 3·4% (3·0–3·9) 6·5% (5·8–7·1) 10·7% (9·8–11·7) 16·5% (15·2–18·0)
Lung 0·1% (0·0–0·1) 0·3% (0·2–0·5) 0·9% (0·7–1·2) 1·9% (1·5–2·3) 3·1% (2·6–3·7) 5·1% (4·3–6·0)
Other 0·5% (0·4–0·7) 1·3% (1·0–1·5) 2·5% (2·2–2·9) 4·7% (4·2–5·3) 7·8% (7·0–8·6) 11·9% (10·7–13·2)
First primary neoplasm: female thyroid
Total subsequent primary 
neoplasms||
1·1% (0·8–1·4) 2·9% (2·5–3·5) 5·5% (4·7–6·2) 8·8% (7·8–9·9) 13·2% (11·8–14·8) 18·2% (16·1–20·5)
Breast 0·5% (0·3–0·7) 1·2% (0·9–1·6) 2·4% (1·9–2·9) 4·2% (3·5–5·0) 5·9% (4·9–7·0) 8·2% (6·7–9·8)
Other 0·6% (0·4–0·8) 1·8% (1·4–2·2) 3·1% (2·6–3·7) 4·8% (4·1–5·7) 7·6% (6·5–8·9) 10·7% (8·9–12·5)
Data are incidence (%, 95% CI). The cumulative risks for the specific subsequent primary neoplasms add up to more than the overall cumulative risk because survivors can 
develop more than one subsequent primary neoplasm. *All subsequent primary neoplasms in female survivors excluding subsequent primary neoplasms of the breast. 
†All subsequent primary neoplasms in female survivors excluding subsequent primary neoplasms of female genital sites. ‡All subsequent primary neoplasms in male 
survivors excluding subsequent primary neoplasms of other male genital sites (prostate sites allowed). §All solid subsequent primary neoplasms in female survivors 
(excluding non-solid tumours). ¶All solid subsequent primary neoplasms in male survivors (excluding non-solid tumours). ||All subsequent primary neoplasms in female 
survivors excluding subsequent primary neoplasms of the thyroid.
Table 5: Cumulative incidence of specific subsequent primary neoplasms after specific first primary neoplasms by years from diagnosis
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neoplasm corresponding to 15 and 11 excess neo-
plasms, respectively (male survivors: SIR 1·7 [95% CI 
1·5–1·9]; AER 14·8 per 10 000 person-years [95% CI 
10·7–19·0]; female survivors: SIR 1·3 [1·2–1·5]; 
AER 11·1 [7·0–15·2]). A statistically significant reduction 
in the SIR for the development of a subsequent primary 
breast cancer was found (SIR 0·7, 95% CI 0·6–0·8; 
table 3). The cumulative incidence of all subsequent 
primary neoplasms was 11·9% (95% CI 10·6–13·3) in 
female survivors of CNS tumours and 10·0% (8·7–11·4) 
in male survivors of CNS tumours at 35 years from 
diagnosis (table 2), whereas an incidence of 9·4% was 
expected.
Sensitivity analyses showed that inclusion of leukaemia 
after AYA Hodgkin lymphoma, non-Hodgkin lymphoma, 
and leukaemia had little effect on the SIRs and AERs 
(appendix p 10). Inclusion of sarcomas after AYA soft-
tissue sarcoma and bone tumour increased the AERs, 
but there was substantial overlap in confidence intervals 
(appendix p 10).
Discussion
We show that the excess number of subsequent primary 
neoplasms observed increases with increased period of 
follow-up from diagnosis after each AYA cancer 
investigated. In patients who had survived at least 
30 years from diagnosis of cervical cancer, testicular 
cancer, Hodgkin lymphoma in women, breast cancer, 
and Hodgkin lymphoma in men, we identified just a 
small number of specific subsequent primary neoplasms 
that account for 82%, 61%, 58%, 45%, and 41% of the 
total excess number of neoplasms, respectively. To our 
knowledge, our study is the first to report excess risks of 
specific types of subsequent primary neoplasms after 
each of 16 types of AYA cancer. One study has previously 
addressed the risk of all subsequent primary neoplasms 
combined after each AYA cancer,3 but no study has 
previously considered specific subsequent primary 
neoplasms.
In our study, the burden of the excess number of 
neoplasms beyond 30 years from diagnosis accounted for 
by lung cancer was substantial and apparent across all 
AYA cancers investigated (breast, cervical, testicular, and 
Hodgkin lymphoma in males and females). It is well 
known that smoking is carcinogenic and the main risk 
factor for developing lung cancer. Additionally, smoking 
increases the risk of developing subsequent primary 
neoplasms, particularly oral or pharyngeal, oesophageal, 
stomach, lung, and haematological malignancies.21 Kaul 
and colleagues22 reported that 33% of survivors of AYA 
cancer were current smokers compared with 22% in a 
non-cancer comparison group matched on age, sex, and 
other factors. This finding confirmed earlier work that 
AYA cancer survivors smoke in excess.23 Young female 
survivors have a higher risk of being a current smoker 
compared with young male survivors, and this difference 
is largely accounted for by cervical cancer.24 Consistent 
with our findings, Underwood and colleagues25 reported 
that survivors of cervical cancer have a two-fold increased 
risk of developing smoking-related cancers compared 
with the general population. Studies have shown that 
smoking is a risk factor for developing lung cancer in 
survivors of breast cancer26 and Hodgkin lymphoma,27 
and that this risk is further enhanced in patients who 
have been treated with radiotherapy (for breast cancer 
and Hodgkin lymphoma) and chemotherapy (for 
Hodgkin lymphoma). We observed a decrease in the 
number of excess lung cancers in male survivors of 
Hodgkin lymphoma with more recent diagnosis. 
Although this decrease could be caused by a number of 
factors, it might be related to a change in smoking habits 
in more recent decades (ie, a reduction in male smokers). 
The evidence presented in our study, along with previous 
literature on smoking in cancer survivors, clearly 
suggests that clinical follow-up of survivors of AYA 
cancer, particularly survivors of breast cancer, cervical 
cancer, and Hodgkin lymphoma, should focus on 
subsequent lung cancer and provision of smoking 
cessation advice.
Generally, it is difficult to compare risks of subsequent 
primary neoplasms between survivors of AYA and 
childhood cancer because there are so many important 
confounding influences. However, lung cancer as a 
subsequent primary neoplasm is an exception to this 
general rule in that from our population-based national 
cohort of survivors of childhood cancer in Britain, we 
reported that in survivors aged 40 years and older, lung 
cancer was associated with an AER of only 2·9 per 
10 000 person-years (95% CI 0·4–5·5), which accounted 
for just 9% of the total AER.28 By contrast, in the present 
analysis, the AER for lung cancer after at least 30 years 
from diagnosis of AYA cancer was substantially higher 
and accounted for a much greater proportion of the total 
AER. Notably, by contrast with survivors of AYA cancer, 
the odds ratio for being a current regular smoker 
among survivors of childhood cancer in Britain was 
0·51 compared with the general population of Britain.29
In female survivors of breast cancer, the SIRs reported 
in our study were broadly consistent with those reported 
in previous literature.5–7 The increased risk of ovarian 
cancer could relate to shared hormonal and genetic 
(eg, BRCA1 and BRCA2 mutations) risk factors.30 The 
increased risk of uterine cancers might relate to partial 
oestrogen agonists used to treat the breast cancer—a 
previous large case-control study found that risk of 
uterine cancer increases with duration of tamoxifen 
treatment.31 Of the six anatomical sites at which an excess 
of subsequent primary neoplasms was observed, only the 
lungs would be directly exposed if external-beam 
radiotherapy was used to treat the breast cancer. A 
previous large case-control study showed a dose-response 
relation between radiotherapy and risk of lung cancer in 
breast cancer survivors diagnosed at any age (not 
AYA-specific).26 Existing literature suggests that chest 
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radiotherapy and smoking are both likely contributors to 
the substantial number of excess neoplasms accounted 
for by lung cancer.
The bladder and bowel would be directly exposed if 
external-beam radiotherapy was used to treat cervical 
cancer. A large case-control study showed a dose-
response relation between radiotherapy and the risk of 
both bladder and rectal cancers in cervical cancer 
survivors.32 Existing literature suggests that pelvic 
irradiation and smoking are likely contributors to the 
number of excess neoplasms accounted for by lung, 
colorectal, and bladder cancer. Clinical follow-up of 
survivors of AYA cervical cancer, particularly where pelvic 
irradiation is used, should focus on lung, bowel, and 
bladder cancers.
Treatment for testicular cancer can involve irradiating 
the para-aortic lymph nodes, which might explain the 
excess of subsequent primary neoplasms seen in 
abdominal sites (prostate, bladder, and colorectal). The 
excess of subsequent primary neoplasms observed in the 
abdomen is consistent with international studies of 
testicular cancer survivors.8 The excess of lung subsequent 
primary neoplasms might be caused by radiotherapy to 
the lungs, since previous studies have reported an 
increased risk of lung cancer in survivors of testicular 
cancer who were given chest radiotherapy.8 Clinical 
follow-up of survivors of AYA testicular cancer should 
focus on prostate, bladder, colorectal, and lung cancers.
The lungs would be directly exposed if external-beam 
radiotherapy was used to treat Hodgkin lymphoma; 
previous studies of Hodgkin lymphoma survivors have 
provided evidence of a dose-dependent increase in lung 
cancer risk with radiotherapy with or without chemo-
therapy.27 Our findings are consistent with previous 
large-scale studies of female survivors of Hodgkin 
lymphoma, for which a substantial amount of literature 
already exists, and by contrast with other AYA cancers 
considered here, we have little to add.9–11 Our findings 
support the decrease in lung cancer risk with more 
recent calendar period of diagnosis that was reported in a 
Dutch study of Hodgkin lymphoma survivors.9 This 
decrease might be due to a latency effect, where more 
recently diagnosed survivors simply have not had enough 
time to develop a lung subsequent primary neoplasm, or 
it might be caused by changes in treatment for Hodgkin 
lymphoma during recent decades, including withholding 
radiotherapy or improvements in the delivery of 
radiotherapy resulting in less damage to healthy tissue 
than in previous decades.33 However, because a decrease 
in lung cancer risk was not seen after Hodgkin lymphoma 
in women, it is possible that the decrease in lung cancer 
in men is caused by other environmental influences, 
such as changes in smoking habits. Previous studies 
have reported an increase in the number of excess lung 
cancers with increasing years from diagnosis;9,10 however, 
to our knowledge, our study is the first to report the 
number of excess lung cancers in male and female 
survivors separately. Existing literature suggests that 
treatment (radiotherapy and chemotherapy), in addition 
to smoking, could contribute to the number of excess 
neoplasms accounted for by lung cancer.9 Clinical follow-
up of male survivors of AYA Hodgkin lymphoma should 
focus on lung cancer and provision of smoking cessation 
advice.
Younger age at radiation exposure is a risk factor for 
the development of breast cancer in many populations 
exposed to radiation, including atomic bomb survivors, 
patients with tuberculosis monitored with x-rays, and 
children with benign disorders treated with radiotherapy.34 
Thus, the effect of age at diagnosis (closely related to age 
at radiotherapy) of Hodgkin lymphoma on the risk of 
breast cancer in our cohort is not surprising.
Knowledge of late effects of cancer treatment has 
resulted in lower radiation exposures for treatments of 
good prognosis cancers in recent years;35 however, the 
multivariable regression showed that the risk of 
developing a subsequent primary neoplasm did not vary 
with decade of diagnosis of AYA cancer apart from lung 
cancer after Hodgkin lymphoma in males. Therefore, 
currently there is little evidence of a detectable impact.
Until recently, no internationally agreed clinical guide-
lines existed regarding surveillance for specific types of 
neoplasm after AYA cancer, but this is now being 
addressed by the International Late Effects of Childhood 
Cancer Guideline Harmonization Group.36 So far, 
two such guidelines have been published.37,38 There are 
also guidelines in development relating to second primary 
CNS tumours and second primary bowel cancers.
Strengths of our cohort study relate to its large scale 
and population-based design, with the inclusion of all 
5-year survivors of AYA cancer in England and Wales. 
The study design minimises selection bias and the 
results are generalisable to the English and Welsh 
population. Our study had much greater statistical power 
than the only comparable previous study by Lee and 
colleagues,3 because we report almost double the number 
of subsequent primary neoplasms and an additional 
million person-years of follow-up. Most previous studies 
investigating the risk of subsequent primary neoplasms 
with years from diagnosis have mainly focused on the 
SIR, a measure of multiplicative risk that relates to an 
unspecified baseline risk and is therefore difficult to 
interpret. We concentrated on the AER, which is the 
excess number of subsequent primary neoplasms 
beyond those expected from the general population, and 
so is directly interpretable in terms of adverse health 
impact on survivors. To our knowledge, our study is the 
first to report AERs by years from diagnosis for each 
specific AYA cancer.
A limitation of using cancer registration data is the 
absence of detailed treatment information. Treatment for 
AYA cancer varies greatly by cancer type; therefore, in the 
absence of treatment data, we chose to determine risks in 
relation to specific cancer types. However, inevitably 
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In conclusion, our data show that the excess number of 
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cancer, Hodgkin lymphoma, and breast cancer, we 
identified just a small number of specific subsequent 
primary neoplasms that account for high proportions of 
the total excess number of neoplasms. A notable finding 
was the excess number of neoplasms accounted for by 
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in addition to subsequent primary neoplasms occurring 
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evidence base for clinical follow-up relating specifically to 
the AYA population.
Contributors
CJB did the literature search and data analysis, created the figure, 
and drafted the report. CJB, RCR, DLW, and MMH carried out the data 
collection. CJB, RCR, DLW, MMH, CF, DPS, MGM, and ABE 
interpreted the data, and reviewed and finalised the report.
Declaration of interests
DPS reports grants from Teenage Cancer Trust, outside the submitted 
work. All other authors declare no competing interests.
Acknowledgments
This study was funded by Cancer Research UK (grant number 
C386/A11709). Other funding was provided by a post-doctoral fellowship to 
RCR from the National Institute for Health Research (PDF-2012-05-280), 
and by the Academy of Medical Sciences (Springboard - Health of the 
Public 2040) and Children with Cancer UK. The Teenage and Young Adult 
Cancer Survivor Study acknowledges and thanks its data providers: the 
Office for National Statistics, Welsh Cancer Registry, and NHS Digital. 
Study collaborators include Sarah Darby (University of Oxford); Richard 
Feltbower (University of Leeds); Lorna Anne Fern (University College 
London); Diana Greenfield (Sheffield Teaching Hospital NHS Foundation 
Trust); Helen Alexandra Spoudeas (University College London Hospitals 
NHS Foundation Trust); William Hamish Wallace (Royal Hospital for Sick 
Articles
www.thelancet.com/oncology   Vol 20   April 2019 545
21 Tabuchi T, Ito Y, Ioka A, Nakayama T, Miyashiro I, Tsukuma H. 
Tobacco smoking and the risk of subsequent primary cancer among 
cancer survivors: a retrospective cohort study. Ann Oncol 2013; 
24: 2699–704.
22 Kaul S, Veeranki SP, Rodriguez AM, Kuo Y-F. Cigarette smoking, 
comorbidity, and general health among survivors of adolescent and 
young adult cancer. Cancer 2016; 122: 2895–905.
23 Tai E, Buchanan N, Townsend J, Fairley T, Moore A, Richardson LC. 
Health status of adolescent and young adult cancer survivors. 
Cancer 2012; 118: 4884–91.
24 Shoemaker ML, White MC, Hawkins NA, Hayes NS. Prevalence of 
smoking and obesity among U.S. cancer survivors: estimates from 
the National Health Interview Survey, 2008–2012. Oncol Nurs Forum 
2016; 43: 436–41.
25 Underwood JM, Rim SH, Fairley TL, Tai E, Stewart SL. Cervical 
cancer survivors at increased risk of subsequent tobacco-related 
malignancies, United States 1992–2008. Cancer Causes Control 2012; 
23: 1009–16.
26 Grantzau T, Thomsen MS, Vaeth M, Overgaard J. Risk of second 
primary lung cancer in women after radiotherapy for breast cancer. 
Radiother Oncol 2014; 111: 366–73.
27 Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer 
following chemotherapy and radiotherapy for Hodgkin’s disease. 
J Natl Cancer Inst 2002; 94: 182–92.
28 Reulen RC, Frobisher C, Winter DL, et al. Long-term risks of 
subsequent primary neoplasms among survivors of childhood 
cancer. JAMA 2011; 305: 2311–19.
29 Frobisher C, Winter DL, Lancashire ER, et al. Extent of smoking 
and age at initiation of smoking among adult survivors of childhood 
cancer in Britain. J Natl Cancer Inst 2008; 100: 1068–81.
30 Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast 
and ovarian cancer. Hum Mol Genet 2001; 10: 705–13.
31 Swerdlow AJ, Jones ME, for the British Tamoxifen Second Cancer 
Study Group. Tamoxifen treatment for breast cancer and risk of 
endometrial cancer: a case-control study. J Natl Cancer Inst 2005; 
97: 375–84.
32 Boice JD Jr, Engholm G, Kleinerman RA, et al. Radiation dose and 
second cancer risk in patients treated for cancer of the cervix. 
Radiat Res 1988; 116: 3–55.
33 Hodgson DC. Late effects in the era of modern therapy for Hodgkin 
lymphoma. Hematology Am Soc Hematol Educ Program 2011; 
2011: 323–29.
34 Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, 
Boice JD Jr. Radiation effects on breast cancer risk: a pooled 
analysis of eight cohorts. Radiat Res 2002; 158: 220–35.
35 Ahmad SS, Duke S, Jena R, Williams MV, Burnet NG. Advances in 
radiotherapy. BMJ 2012; 345: e7765.
36 Kremer LC, Mulder RL, Oeffinger KC, et al. A worldwide 
collaboration to harmonize guidelines for the long-term follow-up 
of childhood and young adult cancer survivors: a report from the 
International Late Effects of Childhood Cancer Guideline 
Harmonization Group. Pediatr Blood Cancer 2013; 60: 543–49.
37 Mulder RL, Kremer LCM, Hudson MM, et al. Recommendations 
for breast cancer surveillance for female survivors of childhood, 
adolescent, and young adult cancer given chest radiation: a report 
from the International Late Effects of Childhood Cancer Guideline 
Harmonization Group. Lancet Oncol 2013; 14: e621–e29.
38 Clement SC, Kremer LCM, Verburg FA, et al. Balancing the 
benefits and harms of thyroid cancer surveillance in survivors of 
childhood, adolescent and young adult cancer: recommendations 
from the International Late Effects of Childhood Cancer Guideline 
Harmonization Group in collaboration with the PanCareSurFup 
Consortium. Cancer Treat Rev 2018; 63: 28–39.
